Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

Prostate Cancer Clinical Trial

Official title:

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01961713
• Other study ID #: 08-207
• Status: Recruiting
• Start date: April 2010
• Est. completion date: December 2025

Study information

• Verified date: May 2024
• Source: Massachusetts General Hospital
• Contact: Richard J Lee, MD, PhD
• Phone: 617-724-4000
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will evaluate a method to detect tumor cells that are circulating in the blood without getting a biopsy. The investigators already know from other studies that cancer tumors shed a small number of cells into the bloodstream every day. These are called circulating tumor cells (CTCs). Some early studies indicate the amount and type of CTCs in the blood can help determine the status of the tumor itself and the way it is responding to treatment. In this study, the investigators will compare the number of CTCs in the blood at different time frames before and after surgery to remove the prostate.

Description:

The investigators will collect a blood sample for the study when the participant has other blood tests drawn for their cancer treatment. The investigators will take one sample to check prostate specific antigen (PSA) levels and another blood sample for CTC analysis. The investigators will be drawing blood at the following time points: Screening; One day after surgery; 7-14 days after surgery; 3-6 months after surgery; at PSA recurrence or at two years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male

• 18 years of age or older

• Pathologically confirmed diagnosis of prostate adenocarcinoma

• Non-metastatic prostate cancer

• Planned radical prostatectomy at Massachusetts General Hospital

Exclusion Criteria:

• Patients must not have received prior radiation therapy, hormone therapy, or other medical therapy for prostate cancer prior to prostatectomy. Post-prostatectomy therapy at the discretion of the patient's treating physician(s) is allowed.

• Patients must not have metastatic prostate cancer

• No prior or current diagnosis of epithelial malignancy, except for skin cancer (squamous cell carcinoma or basal cell carcinoma)

Related Conditions & MeSH terms

• Neoplastic Cells, Circulating
• Prostate Cancer
• Prostatic Neoplasms

Locations

Country	Name	City	State
United States	Massachsuetts General Hospital	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Massachusetts General Hospital	Prostate Cancer Foundation Clinical Research Consortium

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relationship between CTC quantity and pathologic stage	To evaluate the relationship between pre-operative CTC quantity and pathologic stage in men with early stage prostate cancer undergoing prostatectomy. Processing of the pathology specimen will require up to 2 weeks after surgery.	Up to 2 weeks after prostatectomy
Primary	Persistent CTC and biochemical recurrence	To examine the relationship between persistent CTCs and biochemical recurrence after radical prostatectomy for localized prostate cancer	2 year
Secondary	Compare chromosome translocation status	To compare the chromosome translocation status (TMPRSS2 fusion with ETS-related genes ERG, ETV1, ETV4, or ETV5) in CTCs with the primary tumor, and examine potential correlations between specific chromosomal translocations with biochemical recurrence.	2 years
Secondary	Explore other uses of CTCs captured	To explore hypotheses about other uses of the CTCs captured with teh CTC-Chip, or the RNA or protein isolated from the CTCs, from the patients with localized prostate cancer for potential research and clinical applications.	10 years